Head and Neck Diseases

Manel Maños Pujol

  • Miren Taberna Sanz
  • Miriam Handam Zavarce
  • Julio Nogues
  • Enric Cisa Lluis
  • Aleix Rovira Casas
  • Mireia Melero Luque
  • Oriol Bermejo Segu
  • Jordi Tornero Salto
  • Montserrat Goma Gallego
  • Monica Cos Domingo
  • Javier Skufca Vieitez
  • Anna Farre Guiu
  • Marc Oliva Bernal
  • Henry Lares Archer
  • Francesc Cruellas Taischik
  • Xavier Gonzalez Compta
  • Carlos Arranz Obispo
  • Ricard Mesia Nin
  • Alicia Lozano Borbalas
  • Maria Plana Serrahima
  • Marta Fulla Campi
  • Gabriel Huguet Llull
  • Lorena Arribas
  • Laura Rodriguez Bel
  • Antoni Mari Roig
  • Carlos Arranz Obispo
  • Maria Sospedra Martinez

Scientific production





Selected publications

  • Zandberg D.P., Algazi A.P., Jimeno A., Good J.S., Fayette J., Bouganim N., Ready N.E., Clement P.M., Even C., Jang R.W., Wong S., Keilholz U., Gilbert J., Fenton M., Braña I., Henry S., Remenar E., Papai Z., Siu L.L., Jarkowski A., Armstrong J.M., Asubonteng K., Fan J., Melillo G., Mesía R.. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ?25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. EUROPEAN JOURNAL OF CANCER. 10.1016/j.ejca.2018.11.015
  • Taberna, Miren; Oliva, Marc; Mesia, Ricard;. Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. FRONTIERS IN ONCOLOGY. 10.3389/fonc.2019.00383
  • Guigay J., Tahara M., Licitra L., Keilholz U., Friesland S., Witzler P., Mesía R.. The Evolving Role of Taxanes in Combination With Cetuximab for the Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Evidence, Advantages, and Future Directions. FRONTIERS IN ONCOLOGY. 10.3389/fonc.2019.00668
  • Castet F, Brenes J, Taberna M, Mesía R . The emergence of long-term survivors in recurrent and metastatic squamous cell head and neck cancer.. CURRENT OPINION IN ONCOLOGY. 10.1097/CCO.0000000000000530
  • Marín M, Gudiol C, Castet F, Oliva M, Peiró I, Royo-Cebrecos C, Carratalà J, Mesia R . Bloodstream infection in patients with head and neck cancer: a major challenge in the cetuximab era.. CLINICAL AND TRANSLATIONAL ONCOLOGY. 10.1007/s12094-018-1905-5

Research highlights


1 Ongoing project
1 Started project


9 Ongoing clinical trials
5 Started clinical trials

Selected projects

  • Impacto de los cambios de composición corporal en los pacientes con cáncer de cabeza y cuello durante el tratamiento con inmunoterapia (25/6/2019 – 31/12/2020) PI: ARRIBAS HORTIGUELA, LORENA. Funder: DEPARTAMENT SALUT (PR).
  • Estudio de fase I para evaluar la seguridad, la tolerabilidad y la eficacia de VCN-01 en combinación con Durvalumab (MEDI4736) en pacientes con carcinoma de células escamosas de cabeza y cuello recurrente / metastásico. (20/2/2019 – 20/2/2024) PI: MESIA NIN, RICARD. Funder ref.: ICO-VCN-H&N-2018.
  • A phase II study of Durvalumab (MEDI4736) Plus Tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma-the duthy trial (28/2/2019 – 28/2/2025) PI: TABERNA SANZ, MIREN. Funder ref.: GETNE-T1812.
  • A phase 3, multicenter, randomized, open-label, active-controlled study of DS-8201A, an anti-HER2-antibody drug conjugate, versus treatment of investigator’s choice for HER2-positive, unresectable and/or metastatic breast cancer subjects pretreated with prior standard of care her2 therapies, including T-DMI (20/6/2019 – ) PI: VAZQUEZ FERNANDEZ, SILVIA. Funder ref.: DS8201-A-U301.
  • The aim-HN and SEQ-HN study: a 2 cohort, non-comparative, pivotal study evaluating the efficacy of Tipifarnib in patients with head and neck squamous cell carcinoma (HNSCC) with hras mutations (AIM-HN) and the impact of hras mutations on response to first line systemic therapies for HNSCC (SEQ-HN) (27/5/2019 – ) PI: TABERNA SANZ, MIREN. Funder ref.: KO-TIP-007.
  • A phase I dose-escalation/dose expansión study of NBTXR3 activated by intensity modulated radiation therapy in patients with locally advanced squamous cell carcinoma of the joral cavity or Oropharynx (18/7/2019 – ) PI: TABERNA SANZ, MIREN. Funder ref.: NBTXR3-102.